# A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

> **NCT00316524** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 745 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** MVA-BN® (IMVAMUNE)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00316524
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-02
- **Final completion:** 2007-08
- **Target enrollment:** 745 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316524, "A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00316524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*